Congress and the Biden Administration are currently pursuing substantial drug pricing reforms as part of the reconciliation legislation expected to move this fall.  While the focus is primarily on Medicare, Medicaid should not be overlooked.

In an ongoing series of posts for the Commonwealth Fund’s To the Point blog, I examine some key Medicaid drug pricing issues that Congress and the Administration could also consider:

1. Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated Approval Drugs
2. How Medicare Drug Pricing Proposals Could Affect Medicaid
3. Oregon Seeks to Limit Medicaid Coverage of Accelerated-Approval Drugs